keyword
MENU ▼
Read by QxMD icon Read
search

Atezolizumab

keyword
https://www.readbyqxmd.com/read/28205191/novel-and-expanded-oncology-drug-approvals-of-2016-part-1-new-options-in-solid-tumor-management
#1
REVIEW
Todd C Knepper, James Saller, Christine M Walko
The nonradiologic medical management of solid tumors has evolved from the use of traditional cytotoxic agents to modern targeted therapies, monoclonal antibodies, and immunotherapies. Advances in the understanding of cancer biology and therapeutic strategies have resulted in increasing numbers of new drug applications and approvals. Consequently, practicing oncologists need to learn how the newly available agents function and what toxicities to watch for, as well as ways to optimize the use of both new drugs and previously approved drugs with new indications...
February 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28190531/cutaneous-adverse-effects-of-the-immune-checkpoint-inhibitors
#2
REVIEW
Lindsey K Collins, M Shane Chapman, Joi B Carter, Faramarz H Samie
The immune checkpoint targeted agents, anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and anti-programed cell death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitors are frequently associated with cutaneous side effects that are often dose limiting and can lead to discontinuation of therapy. Ipilimumab, a CTLA-4 inhibitor, is most commonly associated with a morbilliform eruption on the trunk and extremities and pruritus. More severe cutaneous toxicities reported include toxic epidermal necrolysis and severe drug rash with eosinophila and systemic symptoms...
December 14, 2016: Current Problems in Cancer
https://www.readbyqxmd.com/read/28134806/systemic-immunotherapy-for-urothelial-cancer-current-trends-and-future-directions
#3
REVIEW
Shilpa Gupta, David Gill, Austin Poole, Neeraj Agarwal
Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, there were very limited options for patients who are refractory to chemotherapy, or do not tolerate chemotherapy due to toxicities and overall outcomes have remained very poor. While the role of immunotherapy was first established in non-muscle invasive bladder cancer in the 1970s, no systemic immunotherapy was approved for advanced disease until the recent approval of a programmed death ligand-1 (PD-L1) inhibitor, atezolizumab, in patients with advanced/metastatic UC who have progressed on platinum-containing regimens...
January 27, 2017: Cancers
https://www.readbyqxmd.com/read/28043166/pharmacokinetic-drug-evaluation-of-atezolizumab-for-the-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma
#4
REVIEW
Rutveej Patel, Megan Bock, Charles F Polotti, Sammy Elsamra
Muscle invasive bladder cancer (MIBC) is difficult to manage for patients who progress during or after initial chemotherapy regimens. Current regimens offer low response rates with high toxicities. The advent of immune checkpoint inhibitors may represent a new opportunity for effective management of these patients. Areas covered: Atezolizumab is an engineered humanized monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1 and B7-1. It is administered intravenously and is given every 3 weeks as long as there is no evidence of tumor progression...
February 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28031561/bladder-cancer-atezolizumab-an-alternative-to-cisplatin
#5
Peter Sidaway
No abstract text is available yet for this article.
December 29, 2016: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28031559/urological-cancer-atezolizumab-an-alternative-to-cisplatin
#6
Peter Sidaway
No abstract text is available yet for this article.
December 29, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27997006/-nivolumab-in-second-line-treatment-of-squamous-non-small-cell-lung-cancer
#7
Filippo De Marinis, Antonio Passaro
The treatment of non-small cell lung cancer (NSCLC) is changing dramatically in the last period, considering both non-squamous and squamous disease. In the last five years, the identification of different molecular predictive biomarker (e.g., EGFR, ALK e ROS1) and the utilize of new chemotherapy agents associated or not with antiangiogenics agents (e.g., bevacizumab and nintedanib), allowed the improvement of survival and related responses to these treatments. However, these advances, did not allow an improvement of the same endpoints in the management of NSCLC with squamous cell histology (SCC), where until very recently, docetaxel in monotherapy remained as a corner stone treatment for the second line, although associated with an unfavorable toxicity profile...
December 2016: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/27981577/the-clinical-pharmacokinetics-and-pharmacodynamics-of-atezolizumab-in-metastatic-urothelial-carcinoma
#8
Mark Stroh, Helen Winter, Mathilde Marchand, Laurent Claret, Steve Eppler, Jane Ruppel, Oyewale Abidoye, Siew Leng Teng, Wan-Ting Lin, Sheila Dayog, Rene Bruno, Jin Jin, Sandhya Girish
Atezolizumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting human programmed death-ligand 1, is FDA-approved in metastatic urothelial carcinoma (mUC) and is being investigated in various malignancies. This analysis, based upon 906 patients from two Phase I and one Phase II mUC studies, is the first report of the clinical pharmacokinetics and pharmacodynamics of atezolizumab. Atezolizumab exhibited linear pharmacokinetics over a dose range of 1 - 20 mg/kg, including the labeled 1200 mg dose...
December 16, 2016: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27979383/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell-lung-cancer-oak-a-phase-3-open-label-multicentre-randomised-controlled-trial
#9
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols, Diego L Cortinovis, Joseph Leach, Jonathan Polikoff, Carlos Barrios, Fairooz Kabbinavar, Osvaldo Arén Frontera, Filippo De Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S Chen, Alan Sandler, David R Gandara
BACKGROUND: Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer. METHODS: We did a randomised, open-label, phase 3 trial (OAK) in 194 academic or community oncology centres in 31 countries. We enrolled patients who had squamous or non-squamous non-small-cell lung cancer, were 18 years or older, had measurable disease per Response Evaluation Criteria in Solid Tumors, and had an Eastern Cooperative Oncology Group performance status of 0 or 1...
January 21, 2017: Lancet
https://www.readbyqxmd.com/read/27969529/ps01-62-long-term-safety-and-clinical-activity%C3%A2-of-atezolizumab-monotherapy%C3%A2-in-metastatic-nsclc-final%C3%A2-results-from-a-phase-ia-study-topic-medical-oncology
#10
Michael S Gordon, Roy S Herbst, Leora Horn, Jean-Charles Soria, Leena Gandhi, Enriqueta Felip, Lecia Sequist, David R Spigel, Scott J Antonia, Ani Balmanoukian, Philippe Cassier, Bo Liu, Marcin Kowanetz, Carol O'Hear, Marcella Fassò, Alan Sandler, Scott N Gettinger
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27969524/ps01-57-impower133-a-phase-i-iii-study-of-1l-atezolizumab-with-carboplatin-and-etoposide-in-patients-with-extensive-stage-sclc-topic-medical-oncology
#11
Leora Horn, Martin Reck, Tony Mok, Melissa L Johnson, Xiongwen Tang, Sivuonthanh Lam, Daniel Waterkamp, Ariel Lopez-Chavez, Alan Sandler, Giuseppe Giacconne, Stephen V Liu
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27969523/ps01-56-impower110-phase-iii-trial-comparing-1l-atezolizumab-with-chemotherapy-in%C3%A2-pd-l1-selected-chemotherapy-naive-nsclc-patients-topic-medical-oncology
#12
Roy S Herbst, Filippo De Marinis, Jacek Jassem, Sivuonthanh Lam, Simonetta Mocci, Alan Sandler, Ariel Lopez-Chavez, Yu Deng, Giuseppe Giaccone, David R Spigel
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27969522/ps01-55-impower010-phase-iii-study-of-atezolizumab-vs-bsc-after-adjuvant-chemotherapy-in-patients-with-completely-resected-nsclc-topic-medical-oncology
#13
Eric Vallieres, Enriqueta Felip, Nasser Altorki, Caicun Zhou, Yunxia Zuo, Michael Howland, Fan Xia, Tien Hoang, Alan Sandler, Heather Wakelee
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27969521/ps01-54-evaluation-of-novel-blood-based-biomarkers-with-atezolizumab-monotherapy-in-1l-advanced-or-metastatic-nsclc-b-f1rst-topic-medical-oncology
#14
Mark A Socinski, Joan Schiller, Shaker Dakhil, Shayma Kazmi, Joseph Leach, Sylvia Hu, Sarah M Paul, David S Shames, See Phan, Cindy Yun, Vamsidhar Velcheti
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27969520/ps01-53-first-line-atezolizumab-plus-chemotherapy-in-chemotherapy-naive-patients-with-advanced-nsclc-a-phase-iii-clinical-program-topic-medical-oncology
#15
Robert M Jotte, Mark A Socinski, Martin Reck, Vassiliki Papadimitrakopoulou, Howard J West, Tony Mok, Alan Sandler, Simonetta Mocci, Shelley Coleman, Takashi Asakawa, Federico Cappuzzo
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27969443/oral01-04-phase-ii-trial-of-atezolizumab-for-patients-with-pd-l1-selected-advanced-nsclc-birch-updated-efficacy-and-exploratory-biomarker-results-topic-medical-oncology
#16
Heather Wakelee, Jyoti D Patel, Rebecca Heist, Ani Balmanoukian, Benjamin Besse, Enriqueta Felip, Enric Carcereny Costa, Laura Q Chow, Marianna Koczywas, Marina C Garassino, Daniel Christoph, Chee Keong Toh, Melissa L Johnson, Jamie Chaft, Takayasu Kurata, Jiaheng Qiu, Marcin Kowanetz, Shelley Coleman, Simonetta Mocci, Alan Sandler, Scott N Gettinger, Solange Peters
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27960628/antibodies-to-watch-in-2017
#17
Janice M Reichert
Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing evaluation in late-stage clinical studies, which is expected to drive a trend toward first marketing approvals of at least 6-9 mAbs per year in the near-term. In the United States (US), a total of 6 and 9 mAbs were granted first approvals during 2014 and 2015, respectively; all these products are also approved in the European Union (EU). As of December 1, 2016, 6 mAbs (atezolizumab, olaratumab, reslizumab, ixekizumab, bezlotoxumab, oblitoxaximab) had been granted first approvals during 2016 in either the EU or US...
February 2017: MAbs
https://www.readbyqxmd.com/read/27939400/atezolizumab-as-first-line-treatment-in-cisplatin-ineligible-patients-with-locally-advanced-and-metastatic-urothelial-carcinoma-a-single-arm-multicentre-phase-2-trial
#18
MULTICENTER STUDY
Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, Thomas Powles, Daniel P Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman-Censits, Jose Luis Perez-Gracia, Nancy A Dawson, Michiel S van der Heijden, Robert Dreicer, Sandy Srinivas, Margitta M Retz, Richard W Joseph, Alexandra Drakaki, Ulka N Vaishampayan, Srikala S Sridhar, David I Quinn, Ignacio Durán, David R Shaffer, Bernhard J Eigl, Petros D Grivas, Evan Y Yu, Shi Li, Edward E Kadel, Zachary Boyd, Richard Bourgon, Priti S Hegde, Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O Abidoye, Gregg D Fine, Dean F Bajorin
BACKGROUND: First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients. METHODS: For this single-arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible...
7, 2017: Lancet
https://www.readbyqxmd.com/read/27928185/drug-monographs-atezolizumab-and-everolimus
#19
Matthew A Green, J Aubrey Waddell, Dominic A Solimando
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast...
November 2016: Hospital Pharmacy
https://www.readbyqxmd.com/read/27920704/autoimmune-hemolytic-anemia-as-a-complication-of-nivolumab-therapy
#20
Amruth R Palla, Devin Kennedy, Hossain Mosharraf, Donald Doll
Recently, immunotherapeutic drugs, including PD-1 inhibitors (nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, avelumab), and CTLA4 inhibitors (ipiliumumab), have emerged as important additions to the armamentarium against certain malignancies and have been incorporated into therapeutic protocols for first-, second-, or third-line agents for these metastatic cancers. Immune checkpoint inhibitor nivolumab is currently FDA approved for the treatment of patients with metastatic malignant melanoma [Redman et al...
September 2016: Case Reports in Oncology
keyword
keyword
77517
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"